TR201815173T4 - Peptit bileşimleri. - Google Patents

Peptit bileşimleri. Download PDF

Info

Publication number
TR201815173T4
TR201815173T4 TR2018/15173T TR201815173T TR201815173T4 TR 201815173 T4 TR201815173 T4 TR 201815173T4 TR 2018/15173 T TR2018/15173 T TR 2018/15173T TR 201815173 T TR201815173 T TR 201815173T TR 201815173 T4 TR201815173 T4 TR 201815173T4
Authority
TR
Turkey
Prior art keywords
peptide compounds
polypeptide
disorders
diseases
treatment
Prior art date
Application number
TR2018/15173T
Other languages
English (en)
Turkish (tr)
Inventor
Sharma Shubh
H T Van Der Ploeg Leonardus
Henderson Bart
Original Assignee
Rhythm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhythm Pharmaceuticals Inc filed Critical Rhythm Pharmaceuticals Inc
Publication of TR201815173T4 publication Critical patent/TR201815173T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TR2018/15173T 2013-03-15 2014-03-14 Peptit bileşimleri. TR201815173T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361790469P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
TR201815173T4 true TR201815173T4 (tr) 2018-11-21

Family

ID=50588892

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/15173T TR201815173T4 (tr) 2013-03-15 2014-03-14 Peptit bileşimleri.

Country Status (10)

Country Link
US (4) US10196425B2 (enExample)
EP (2) EP2970388B1 (enExample)
JP (4) JP6622690B2 (enExample)
CN (3) CN118240012A (enExample)
AU (6) AU2014227712B2 (enExample)
CA (1) CA2906694A1 (enExample)
ES (1) ES2693761T3 (enExample)
RU (2) RU2725150C2 (enExample)
TR (1) TR201815173T4 (enExample)
WO (1) WO2014144260A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100734T1 (it) 2011-12-29 2022-03-21 Rhythm Pharmaceuticals Inc Metodo di trattamento di disturbi associati al recettore di melanocortina 4 in portatori eterozigoti
JP6538025B2 (ja) 2013-03-15 2019-07-03 リズム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物
JP6622690B2 (ja) * 2013-03-15 2019-12-18 リズム・ファーマシューティカルズ・インコーポレイテッド ペプチド組成物
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
MX2018003983A (es) * 2015-09-30 2018-11-09 Rhythm Pharmaceuticals Inc Metodo de tratamiento de trastornos asociados a la via del receptor de melanocortina-4.
WO2018065345A1 (en) * 2016-10-04 2018-04-12 Dsm Ip Assets B.V. Melanocortin-1-receptor agonists
US20200223889A1 (en) * 2017-03-15 2020-07-16 Novo Nordisk A/S Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor
CA3096055A1 (en) 2018-04-06 2019-10-10 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
WO2020053414A1 (en) * 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
JP2023542985A (ja) * 2020-09-24 2023-10-12 リズム ファーマシューティカルズ， インコーポレイテッド メラノコルチン－４受容体経路関連障害の治療方法
CN113209270B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备防治急性肝衰竭药物中的应用
CN113332416B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备治疗非酒精性脂肪肝药物中的应用
JP2024532294A (ja) * 2021-08-24 2024-09-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｃ４ｒアゴニストペプチド
CN116789802A (zh) * 2023-06-25 2023-09-22 湖北省农业科学院畜牧兽医研究所 一种山羊mc4r增强型突变体及其应用
WO2025131101A1 (zh) * 2023-12-22 2025-06-26 上海多米瑞生物技术有限公司 多肽化合物、其药物组合物及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0292291B1 (en) * 1987-05-22 1994-08-10 University Patents, Inc. Linear and cyclic analogs of alpha-msh fragments with extraordinary potency
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
GB9827500D0 (en) * 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
PT1315750E (pt) * 2000-08-30 2007-05-31 Hoffmann La Roche Péptidos cíclicos com actividade agonista para o receptor 4 de melanocortina
AU2002322466B2 (en) * 2001-07-11 2007-08-30 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
FR2851563B1 (fr) 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
EA200600055A1 (ru) * 2003-06-19 2006-08-25 Эли Лилли Энд Компани Агонисты рецептора меланокортина 4 (мк4 ) и их применение
WO2005000338A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
FR2862971B1 (fr) 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US8343031B2 (en) * 2004-03-23 2013-01-01 Michael Gertner Obesity treatment systems
FR2872165B1 (fr) 2004-06-24 2006-09-22 Sod Conseils Rech Applic Nouveaux derives de pyrimido-benzimidazole
EP1915168A4 (en) 2005-07-08 2010-03-31 Ipsen Pharma LIGANDS OF MELANOCORTIN RECEPTORS
ES2663916T3 (es) 2005-07-08 2018-04-17 Ipsen Pharma Ligandos de los receptores de la melanocortina
CA2689016C (en) 2007-05-25 2014-08-12 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
EP2167112A4 (en) 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
EP2979703B1 (en) 2007-11-05 2018-07-18 Ipsen Pharma S.A.S. Use of melanocortins to treat insulin sensitivity
AR072072A1 (es) * 2008-06-09 2010-08-04 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669
BRPI1009644B1 (pt) * 2009-06-08 2022-02-08 Palatin Technologies, Inc Peptídeo cíclico ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso da composição farmacêutica
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
MX2012001513A (es) 2009-08-05 2012-05-22 Ipsen Pharma Sas Uso de melanocortinas para tratar la dislipidemia.
JP5486690B2 (ja) 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
WO2011060355A1 (en) 2009-11-16 2011-05-19 Ipsen Pharma S.A.S Process for the synthesis of ac-arg-cyclo(cys-d-ala-his-d-phe-arg-trp-cys)-nh2
KR102038677B1 (ko) 2011-06-14 2019-10-30 입센 파마 에스.에이.에스 활성 성분으로 멜라노코르틴 수용체 리간드를 함유하는 지속-방출형 조성물
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
JP6622690B2 (ja) * 2013-03-15 2019-12-18 リズム・ファーマシューティカルズ・インコーポレイテッド ペプチド組成物
JP6538025B2 (ja) * 2013-03-15 2019-07-03 リズム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物

Also Published As

Publication number Publication date
JP7654587B2 (ja) 2025-04-01
EP2970388B1 (en) 2018-07-25
CA2906694A1 (en) 2014-09-18
AU2014227712A1 (en) 2015-10-01
RU2725150C2 (ru) 2020-06-30
US10858399B2 (en) 2020-12-08
EP2970388A1 (en) 2016-01-20
CN118271400A (zh) 2024-07-02
JP6622690B2 (ja) 2019-12-18
JP2016516719A (ja) 2016-06-09
US20190092815A1 (en) 2019-03-28
AU2021269411A1 (en) 2021-12-16
AU2024200528A1 (en) 2024-02-15
AU2026204118A1 (en) 2026-06-11
CN105492456B (zh) 2024-11-01
EP3450449A3 (en) 2019-06-12
RU2020120797A (ru) 2020-07-02
AU2018256493A1 (en) 2018-11-22
US20210040155A1 (en) 2021-02-11
JP2019172693A (ja) 2019-10-10
AU2020203353A1 (en) 2020-06-11
US10196425B2 (en) 2019-02-05
CN118240012A (zh) 2024-06-25
JP7046871B2 (ja) 2022-04-04
US20250188124A1 (en) 2025-06-12
CN105492456A (zh) 2016-04-13
US12077612B2 (en) 2024-09-03
ES2693761T3 (es) 2018-12-13
RU2015145593A (ru) 2017-04-24
US20160017001A1 (en) 2016-01-21
EP3450449A2 (en) 2019-03-06
AU2014227712B2 (en) 2018-08-02
JP2025102830A (ja) 2025-07-08
HK1220697A1 (en) 2017-05-12
JP2022084844A (ja) 2022-06-07
WO2014144260A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
CY1120730T1 (el) Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1
CY1122796T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων
JOP20180103A1 (ar) مركب صيدلاني
EA201591746A1 (ru) Способы и композиции для ингибирования бромодомен-содержащих белков
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
BR112015031073A2 (pt) inibidores bicíclicos de bromodomínio
EA201890239A3 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
BR112015022191A8 (pt) compostos heteroarila e usos dos mesmos
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
JO3357B1 (ar) مركبات إيميدازوبيروليدينون
EA201691582A1 (ru) Новые фармацевтические препараты
EA201690372A1 (ru) Азапиридоновые соединения и их применение
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
EA201690246A1 (ru) Ингибиторы аутотаксинов, содержащие ядро гетероароматическое кольцо-бензил-амидный цикл
EA201300388A1 (ru) Соединения замещенного бензамида
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201590954A1 (ru) Дигидропиразольные модуляторы gpr40
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40